Breast cancer remains a formidable challenge, holding the grim distinction of being the most commonly diagnosed cancer and the leading cause of cancer death among women globally. However, a promising avenue for combating this disease is emerging in the form of necroptosis. Necroptosis offers a unique strategy for tackling breast cancer. It not only eliminates cancer cells that have evaded apoptosis, but also stimulates the immune system to recognize and attack these malignant cells. This dual approach holds immense potential for improved treatment outcomes. The study aims to explore variations in necroptosis-related genes between breast tumor patients and a control group. Then, a polygenic risk score (PRS) will be constructed based on these genetic variants, and it will be further validated to assess its effectiveness. The project duration is about 3 years. The outcomes of this investigation will shed light on alterations in SNPs within necroptosis-related genes among breast cancer patients. This elucidation will help delineate the influence of these genes on the likelihood of breast cancer development and long-term prognosis. Consequently, these findings hold the potential to furnish clinicians and researchers with valuable insights for early detection of breast cancer risk, formulation of tailored treatment strategies, and evaluation of prognosis.
